Biomarkers such as calcium channel binding protein S100 subunit beta (S100B), glial
fibrillary acidic protein (GFAP), ubiquitin c-terminal hydrolase L1 (UCH-L1) and neuron …

Primary objective: To determine whether S100B protein in serum can predict intracranial
lesions on computed tomography (CT) scan after mild traumatic brain injury (MTBI) …

Objective: To compare the classification accuracy of S100B to two clinical decision rules—
Canadian CT Head Rule (CCHR) and New Orleans Criteria (NOC)—for predicting traumatic …

Background Mild traumatic brain injury (mTBI) is one of the most common causes of
emergency department visits around the world. Up to 90% of injuries are classified as mTBI …

Introduction Patients suffering from severe traumatic brain injury (TBI) often develop
secondary brain lesions that may worsen outcome. S100B, a biomarker of brain damage …

Background The biomarker serum S100 calcium-binding protein B (S100B) is used in in-
hospital triage of adults with mild traumatic brain injury to rule out intracranial lesions. The …

Wiesmann M, Steinmeier E, Magerkurth O, Linn J, Gottmann D, Missler U. Outcome
prediction in traumatic brain injury: comparison of neurological status, CT findings, and …

Both glial fibrillary acidic protein (GFAP) and S100β are found in glial cells and are released
into serum following a traumatic brain injury (TBI), however, the clinical utility of S100β as a …

Objectives: To evaluate the ability of S100B to predict severity of TBI and abnormal cranial
CT results for children with TBI. Methods: This is a secondary analysis of a previously …

Background: This study's primary objective was to validate the routine use of S100B via a
prospective study. The aim was a reduction of cranial computed tomography (CCT) scans by …